Top

Published in:

01-10-2018 | Original Article

Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage

Authors: Bappaditya Ray, Vijay M. Pandav, Eleanor A. Mathews, David M. Thompson, Lance Ford, Lori K. Yearout, Bradley N. Bohnstedt, Shuchi Chaudhary, George L. Dale, Calin I. Prodan

Published in: Translational Stroke Research | Issue 5/2018

Abstract

Aneurysmal subarachnoid hemorrhage (aSAH) is associated with high socio-economic burden. Prothrombotic states of early brain injury (EBI) and delayed cerebral ischemia (DCI) after aSAH determine morbidity and mortality. To understand how activated platelets might contribute to such prothrombotic states, we studied trends in coated-platelets during EBI and DCI periods. Serial blood samples from a prospective cohort of aSAH patients were collected and assayed for coated-platelet levels. Patient’s coated-platelet level during post-hospital discharge follow-up served as an estimate of baseline. Occurrence of DCI, Montreal cognitive assessment (MOCA) score of < 26, and modified Rankin scale (mRS) of 3–6 were considered poor clinical outcomes. Non-linear regression analysis detected a transition between periods of rising and declining coated-platelet levels at day 4. Additional regression analyses of coated-platelet trends before day 4 showed differences among patients with modified Fisher 3–4 [4.2% per day (95% CI 2.4, 6.1) vs. − 0.8% per day (95% CI − 3.4, 1.8); p = 0.0023] and those developing DCI [4.6% per day (95% CI 2.8, 6.5) vs. − 1.9% per day (95% CI − 4.5, 0.5); p < 0.001]. Differences between peak coated-platelet levels and baseline levels were larger, on average for those with DCI [18.1 ± 9.6 vs. 10.6 ± 8.0; p = 0.03], MOCA < 26 [17.0 ± 7.8 vs. 10.7 ± 7.4; p = 0.05] and mRS 3–6 [24.8 ± 10.5 vs. 11.9 ± 7.6; p = 0.01]. Coated-platelet trends after aSAH predict DCI and short-term clinical outcomes. The degree of rise in coated-platelets is also associated with adverse clinical outcomes.

Brinjikji W, Kallmes DF, Lanzino G, Cloft HJ. Hospitalization costs for endovascular and surgical treatment of ruptured aneurysms in the United States are substantially higher than Medicare payments. AJNR Am J Neuroradiol. 2012;33(6):1037–40. https://doi.org/10.3174/ajnr.A2938. CrossRefPubMed

Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27(9):1459–66. https://doi.org/10.1161/01.STR.27.9.1459.CrossRefPubMed

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463–9. https://doi.org/10.1161/strokeaha.111.648980. CrossRefPubMed

Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618–25. https://doi.org/10.1016/s1474-4422(11)70108-9.CrossRefPubMed

Dhar R, Diringer MN. Relationship between angiographic vasospasm, cerebral blood flow, and cerebral infarction after subarachnoid hemorrhage. Acta Neurochir Suppl. 2015;120:161–5. https://doi.org/10.1007/978-3-319-04981-6_27.PubMedCrossRef

Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44–58. https://doi.org/10.1038/nrneurol.2013.246. CrossRefPubMed

Rowland MJ, Hadjipavlou G, Kelly M, Westbrook J, Pattinson KT. Delayed cerebral ischaemia after subarachnoid haemorrhage: looking beyond vasospasm. Br J Anaesth. 2012;109(3):315–29. https://doi.org/10.1093/bja/aes264.CrossRefPubMed

Vergouwen MD, Vermeulen M, Coert BA, Stroes ES, Roos YB. Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab. 2008;28(11):1761–70. https://doi.org/10.1038/jcbfm.2008.74.CrossRefPubMed

Bendel P, Koivisto T, Aikia M, Niskanen E, Kononen M, Hanninen T et al. Atrophic enlargement of CSF volume after subarachnoid hemorrhage: correlation with neuropsychological outcome. AJNR Am J Neuroradiol. vol 2. United States 2010. p. 370–6.

10.

Tam AK, Kapadia A, Ilodigwe D, Li Z, Schweizer TA, Macdonald RL. Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage. J Neurosurg. 2013;119(1):198–206. https://doi.org/10.3171/2013.3.jns121950.CrossRefPubMed

11.

Romano JG, Forteza AM, Concha M, Koch S, Heros RC, Morcos JJ, et al. Detection of microemboli by transcranial Doppler ultrasonography in aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;50(5):1026–30. discussion 30-1PubMed

12.

Frontera JA, Ahmed W, Zach V, Jovine M, Tanenbaum L, Sehba F, et al. Acute ischaemia after subarachnoid haemorrhage, relationship with early brain injury and impact on outcome: a prospective quantitative MRI study. J Neurol Neurosurg Psychiatry. 2015;86(1):71–8. https://doi.org/10.1136/jnnp-2013-307313.CrossRefPubMed

13.

Frontera JA, Aledort L, Gordon E, Egorova N, Moyle H, Patel A, et al. Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage: a pilot study. J Thromb Haemost : JTH. 2012;10(4):711–3. https://doi.org/10.1111/j.1538-7836.2012.04651.x. CrossRefPubMed

14.

Ikeda K, Asakura H, Futami K, Yamashita J. Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage. Neurosurgery. 1997;41(2):344–349; discussion 9-50. https://doi.org/10.1097/00006123-199708000-00002.CrossRefPubMed

15.

Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Koike T, Tanaka R. Hemostasis in spontaneous subarachnoid hemorrhage. Neurosurgery. 1995;37(2):226–34. https://doi.org/10.1227/00006123-199508000-00006.CrossRefPubMed

16.

Ramchand P, Nyirjesy S, Frangos S, Doerfler S, Nawalinski K, Quattrone F, et al. Thromboelastography parameter predicts outcome after subarachnoid hemorrhage: an exploratory analysis. World Neurosurg. 96:215–21. https://doi.org/10.1016/j.wneu.2016.04.002.

17.

Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010;328(5978):562–4. https://doi.org/10.1126/science.328.5978.562. CrossRefPubMed

18.

Langer HF, Chavakis T. Platelets and neurovascular inflammation. Thromb Haemost. 2013;110(5):888–93. https://doi.org/10.1160/th13-02-0096.PubMedCrossRef

19.

Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost : JTH. 2005;3(10):2185–92. https://doi.org/10.1111/j.1538-7836.2005.01274.x. CrossRefPubMed

20.

Prodan CI, Joseph PM, Vincent AS, Dale GL. Coated-platelets in ischemic stroke: differences between lacunar and cortical stroke. J Thromb Haemost : JTH. 2008;6(4):609–14. https://doi.org/10.1111/j.1538-7836.2008.02890.x. CrossRefPubMed

21.

Prodan CI, Vincent AS, Kirkpatrick AC, Hoover SL, Dale GL. Higher levels of coated-platelets are observed in patients with subarachnoid hemorrhage but lower levels are associated with increased mortality at 30 days. J Neurol Sci. 2013;334(1–2):126–9. https://doi.org/10.1016/j.jns.2013.08.008.CrossRefPubMed

22.

Prodan CI, Vincent AS, Padmanabhan R, Dale GL. Coated-platelet levels are low in patients with spontaneous intracerebral hemorrhage. Stroke. 2009;40(7):2578–80. https://doi.org/10.1161/strokeaha.109.549014. CrossRefPubMed

23.

Vergouwen MD, Vermeulen M, van Gijn J, Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–5. https://doi.org/10.1161/strokeaha.110.589275. CrossRefPubMed

24.

Ishikawa M, Kusaka G, Yamaguchi N, Sekizuka E, Nakadate H, Minamitani H, et al. Platelet and leukocyte adhesion in the microvasculature at the cerebral surface immediately after subarachnoid hemorrhage. Neurosurgery. 2009;64(3):546–553; discussion 53-4. https://doi.org/10.1227/01.neu.0000337579.05110.f4.CrossRefPubMed

25.

Tso MK, Macdonald RL. Subarachnoid hemorrhage: a review of experimental studies on the microcirculation and the neurovascular unit. Transl Stroke Res. 2014;5(2):174–89. https://doi.org/10.1007/s12975-014-0323-4.CrossRefPubMed

26.

Frontera JA, Provencio JJ, Sehba FA, McIntyre TM, Nowacki AS, Gordon E, et al. The role of platelet activation and inflammation in early brain injury following subarachnoid hemorrhage. Neurocrit Care. 2016;26(1):48–57. https://doi.org/10.1007/s12028-016-0292-4.CrossRef

27.

Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis. 2001;12(5):327–37. https://doi.org/10.1097/00001721-200107000-00001.CrossRefPubMed

28.

Ohkuma H, Suzuki S, Kimura M, Sobata E. Role of platelet function in symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke. 1991;22(7):854–9. https://doi.org/10.1161/01.STR.22.7.854.CrossRefPubMed

29.

Nina P, Schisano G, Chiappetta F, Luisa Papa M, Maddaloni E, Brunori A, et al. A study of blood coagulation and fibrinolytic system in spontaneous subarachnoid hemorrhage. Correlation with hunt-hess grade and outcome. Surg Neurol. 2001;55(4):197–203. https://doi.org/10.1016/S0090-3019(01)00402-5.CrossRefPubMed

30.

Hirashima Y, Nakamura S, Endo S, Kuwayama N, Naruse Y, Takaku A. Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage. Neurochem Res. 1997;22(10):1249–55. https://doi.org/10.1023/A:1021985030331.CrossRefPubMed

31.

Sjovall F, Morota S, Hansson MJ, Friberg H, Gnaiger E, Elmer E. Temporal increase of platelet mitochondrial respiration is negatively associated with clinical outcome in patients with sepsis. Crit Care. 2010;14(6):R214. https://doi.org/10.1186/cc9337.CrossRefPubMedPubMedCentral

32.

Puskarich MA, Kline JA, Watts JA, Shirey K, Hosler J, Jones AE. Early alterations in platelet mitochondrial function are associated with survival and organ failure in patients with septic shock. J Crit Care. 2016;31(1):63–7. https://doi.org/10.1016/j.jcrc.2015.10.005.CrossRefPubMed

33.

Stein SC, Browne KD, Chen XH, Smith DH, Graham DI. Thromboembolism and delayed cerebral ischemia after subarachnoid hemorrhage: an autopsy study. Neurosurgery. 2006;59(4):781–787; discussion 7-8. https://doi.org/10.1227/01.neu.0000227519.27569.45.CrossRefPubMed

34.

Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. 2004;103(6):2096–104. https://doi.org/10.1182/blood-2003-08-2804.CrossRefPubMed

35.

Levi M, van der Poll T, Schultz M. Systemic versus localized coagulation activation contributing to organ failure in critically ill patients. Semin Immunopathol. 2012;34(1):167–79. https://doi.org/10.1007/s00281-011-0283-7.CrossRefPubMed

36.

Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510(7503):92–101. https://doi.org/10.1038/nature13479.CrossRefPubMedPubMedCentral

37.

Fredman G, Van Dyke TE, Serhan CN. Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol. 2010;30(10):2005–13. https://doi.org/10.1161/atvbaha.110.209908.CrossRefPubMedPubMedCentral

38.

Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi A, et al. Resolvin E1, an EPA-derived mediator in whole blood, selectively counter regulates leukocytes and platelets. Blood. 2008;112(3):848–55. https://doi.org/10.1182/blood-2007-11-122598.CrossRefPubMedPubMedCentral

39.

Dalli J, Colas RA, Quintana C, Barragan-Bradford D, Hurwitz S, Levy BD, et al. Human sepsis eicosanoid and proresolving lipid mediator temporal profiles: correlations with survival and clinical outcomes. Crit Care Med. 2017;45(1):58–68. https://doi.org/10.1097/ccm.0000000000002014.CrossRefPubMedPubMedCentral

40.

Smith FG, Sheehy AM, Vincent JL, Coursin DB. Critical illness-induced dysglycaemia: diabetes and beyond. Crit Care. 2010;14(6):327. https://doi.org/10.1186/cc9266.CrossRefPubMedPubMedCentral

41.

Stellos K, Katsiki N, Tatsidou P, Bigalke B, Laske C. Association of platelet activation with vascular cognitive impairment: implications in dementia development? Curr Vasc Pharmacol. 2014;12(1):152–4. https://doi.org/10.2174/157016111201140327164641.CrossRefPubMed

42.

Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76(3):247–52. https://doi.org/10.1212/WNL.0b013e3182074bd2.CrossRefPubMedPubMedCentral

43.

McDougall CG, Spetzler RF, Zabramski JM, Partovi S, Hills NK, Nakaji P, et al. The barrow ruptured aneurysm trial. J Neurosurg. 2012;116(1):135–44. https://doi.org/10.3171/2011.8.jns101767.CrossRefPubMed

44.

Molyneux A, Kerr R, Stratton I, Sandercock P, Clarke M, Shrimpton J, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet. 2002;360(9342):1267–74. https://doi.org/10.1016/S0140-6736(02)11314-6.CrossRefPubMed

Title: Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage
Authors: Bappaditya Ray
Vijay M. Pandav
Eleanor A. Mathews
David M. Thompson
Lance Ford
Lori K. Yearout
Bradley N. Bohnstedt
Shuchi Chaudhary
George L. Dale
Calin I. Prodan
Publication date: 01-10-2018
Publisher: Springer US
Published in: Translational Stroke Research / Issue 5/2018
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-017-0594-7

ACC 2024 Congress

Springer Medicine

Coated-Platelet Trends Predict Short-Term Clinical OutcomeAfter Subarachnoid Hemorrhage

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice

Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO−-MMP-9 Pathway

Photothrombotic Stroke as a Model of Ischemic Stroke

Ras-Related C3 Botulinum Toxin Substrate 1 Promotes Axonal Regeneration after Stroke in Mice

Association Between Splenic Contraction and the Systemic Inflammatory Response After Acute Ischemic Stroke Varies with Age and Race

Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model